Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells

Allegri,Lorenzo; Baldan,Federica; Mio,Catia; Puppin,Cinzia; Russo,Diego; Kryštof,Vladimir; Damante,Giuseppe

doi:10.3892/or.2016.4614

Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells

Authors:
- Lorenzo Allegri
- Federica Baldan
- Catia Mio
- Cinzia Puppin
- Diego Russo
- Vladimir Kryštof
- Giuseppe Damante
View Affiliations

Affiliations: Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy, Department of Health Sciences, University ‘Magna Graecia’ of Catanzaro, Catanzaro, Italy, Laboratory of Growth Regulators, Center of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR, CZ-77111 Olomuc, Czech Republic
Published online on: February 5, 2016 https://doi.org/10.3892/or.2016.4614
Pages: 2413-2418

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid carcinoma (ATC) is an extremely aggressive human malignancy characterized by a marked degree of invasiveness, absense of features of thyroid differentiation and resistance to current medical treatment. It is well known that ATCs are characterized by deregulation of genes related to cell cycle regulation, i.e., cyclin-dependent kinases (CDKs) and endogenous cyclin-dependent kinase inhibitors (CDKIs). Therefore, in the present study, the effect of a novel exogenous cyclin-dependent kinase inhibitor, BP-14, was investigated in three human ATC cell lines. The ATC-derived cell lines FRO, SW1736 and 8505C were treated with BP-14 alone or in combination with the mTOR inhibitor everolimus. In all ATC cell lines, treatment with BP-14 decreased cell viability and, in two of them, BP-14 modified expression of genes involved in epithelial-mesenchymal transition. Thus, our data indicate that BP-14 is a potential new compound effective against ATC. Combined treatment with BP-14 and the mTOR inhibitor everolimus had a strong synergistic effect on cell viability in all three cell lines, suggesting that the combined used of CDK and mTOR inhibitors may be a useful strategy for ATC treatment.

View Figures

View References

1	Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
2	O'Neill JP and Shaha AR: Anaplastic thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kojic SL, Strugnell SS and Wiseman SM: Anaplastic thyroid cancer: A comprehensive review of novel therapy. Expert Rev Anticancer Ther. 11:387–402. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wang HM, Huang YW, Huang JS, Wang CH, Kok VC, Hung CM, Chen HM and Tzen CY: Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol. 14:3011–3018. 2007. View Article : Google Scholar : PubMed/NCBI
5	Quiros RM, Ding HG, Gattuso P, Prinz RA and Xu X: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 103:2261–2268. 2005. View Article : Google Scholar : PubMed/NCBI
6	Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK and Xing M: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar : PubMed/NCBI
7	Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
8	McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
9	Russo D, Damante G, Puxeddu E, Durante C and Filetti S: Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol. 46:R73–R81. 2011. View Article : Google Scholar : PubMed/NCBI
10	Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S and Carcangiu ML: Downregulation of p27^KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol. 23:678–685. 1999. View Article : Google Scholar : PubMed/NCBI
11	Pita JM, Figueiredo IF, Moura MM, Leite V and Cavaco BM: Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J Clin Endocrinol Metab. 99:E497–E507. 2014.PubMed/NCBI
12	Gucký T, Jorda R, Zatloukal M, Bazgier V, Berka K, Řezníčková E, Béres T, Strnad M and Kryštof V: A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors. J Med Chem. 56:6234–6247. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, et al: Small molecules and targeted therapies in distant metastatic disease. Ann Oncol. 20(Suppl 6): vi35–vi40. 2009. View Article : Google Scholar : PubMed/NCBI
14	Haider C, Grubinger M, Řezníčková E, Weiss TS, Rotheneder H, Miklos W, Berger W, Jorda R, Zatloukal M, Gucky T, et al: Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance. Mol Cancer Ther. 12:1947–1957. 2013. View Article : Google Scholar : PubMed/NCBI
15	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
16	Pilli T, Prasad KV, Jayarama S, Pacini F and Prabhakar BS: Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid. 19:1333–1342. 2009. View Article : Google Scholar : PubMed/NCBI
17	Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, et al: Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 93:4331–4341. 2008. View Article : Google Scholar : PubMed/NCBI
18	Baldan F, Lavarone E, Di Loreto C, Filetti S, Russo D, Damante G and Puppin C: Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene. Mol Biol Rep. 41:5257–5265. 2014. View Article : Google Scholar : PubMed/NCBI
19	Papewalis C, Wuttke M, Schinner S, Willenberg HS, Baran AM, Scherbaum WA and Schott M: Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res. 41:752–756. 2009. View Article : Google Scholar : PubMed/NCBI
20	Chou TC and Talalay P: Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci. 4:450–454. 1983. View Article : Google Scholar
21	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
22	Denaro N, Nigro CL, Russi EG and Merlano MC: The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther. 9:1231–1241. 2013. View Article : Google Scholar : PubMed/NCBI
23	Schlumberger M, Lacroix L, Russo D, Filetti S and Bidart JM: Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab. 3:260–269. 2007. View Article : Google Scholar : PubMed/NCBI
24	Senderowicz AM: Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol. 16:670–678. 2004. View Article : Google Scholar : PubMed/NCBI
25	Wang S, Wuu J, Savas L, Patwardhan N and Khan A: The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol. 29:1304–1309. 1998. View Article : Google Scholar : PubMed/NCBI
26	Elisei R, Shiohara M, Koeffler HP and Fagin JA: Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15^INK4b and p16^INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer. 83:2185–2193. 1998. View Article : Google Scholar : PubMed/NCBI
27	Rocha AS, Paternot S, Coulonval K, Dumont JE, Soares P and Roger PP: Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell. 19:4814–4825. 2008. View Article : Google Scholar : PubMed/NCBI
28	Li F, Zhao C and Wang L: Molecular-targeted agents combination therapy for cancer: Developments and potentials. Int J Cancer. 134:1257–1269. 2014. View Article : Google Scholar
29	Carracedo A, Baselga J and Pandolfi PP: Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle. 7:3805–3809. 2008. View Article : Google Scholar : PubMed/NCBI
30	Perri F, Lorenzo GD, Scarpati GD and Buonerba C: Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol. 2:150–157. 2011. View Article : Google Scholar : PubMed/NCBI